


## Toxoflavin-<sup>13</sup>C<sub>4</sub>

<b>Cat. No.:</b>	HY-100760S
<b>CAS No.:</b>	2300178-70-3
<b>Molecular Formula:</b>	C <sub>3</sub> <sup>13</sup> C <sub>4</sub> H <sub>6</sub> N <sub>5</sub> O <sub>2</sub>
<b>Molecular Weight:</b>	196.13
<b>Target:</b>	β-catenin; Bacterial; Antibiotic; Isotope-Labeled Compounds
<b>Pathway:</b>	Stem Cell/Wnt; Anti-infection; Others
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Toxoflavin- <sup>13</sup> C <sub>4</sub> is the <sup>13</sup> C-labeled Toxoflavin. Toxoflavin (Xanthothricin) is an antagonist of transcription factor 4 (TCF4)/β-catenin complex, also acts as an inhibitor of KDM4A, with antitumor activity[1][2]. Antibiotic properties.
<b>In Vitro</b>	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother*. 2019;53(2):211-216.
- [2]. Wei W, et al. Small molecule antagonists of Tcf4/beta-catenin complex inhibit the growth of HCC cells in vitro and in vivo. *Int J Cancer*. 2010 May 15;126(10):2426-36.
- [3]. Franci G, et al. Identification and characterization of PKF118-310 as a KDM4A inhibitor. *Epigenetics*. 2017 Mar 4;12(3):198-205.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA